Australia TGA Psilocybin Approval — What Actually Changed in 2023
27 replies · News & Policy
Australia became the first country to formally reschedule psilocybin for therapeutic use in 2023. As an Australian user watching this closely, I want to break down what the TGA decision actually did vs. what coverage made it sound like, because there's a lot of confusion in the international community about what 'approval' means.
What changed: psilocybin (and MDMA) were moved from Schedule 9 (prohibited) to Schedule 8 (controlled drug) for use in TGA-authorized therapeutic settings. This means authorized psychiatrists can prescribe them to specific patients through an Authorized Prescriber or Special Access Scheme pathway. It's not a general prescription drug; it's tightly restricted to authorized specialists.
What didn't change: it's still not available to most Australians. The authorized prescriber pathway requires psychiatrists who meet specific criteria and have approved treatment settings. The training infrastructure, clinic availability, and approved prescriber numbers are still catching up to the legal change. As of 2024-2025, access remains extremely limited in practice.
For Americans watching: the TGA model is different from Oregon's service center model. Australia routed it through the medical system (prescribers, clinics, insurance potential eventually). Oregon created an entirely new category of 'facilitation' outside medical practice. Both are real but represent different bets about what implementation should look like.
24 more replies — forum posting coming soon.